within Pharmacolibrary.Drugs.ATC.J;

model J05AJ04_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.020300000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0149,
    k12             = 0.408,
    k21             = 0.408
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AJ04_1</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cabotegravir is a long-acting integrase strand transfer inhibitor (INSTI) used for the treatment and prevention of HIV-1 infection in adults and adolescents. It is approved for use in combination with rilpivirine for both treatment and pre-exposure prophylaxis (PrEP).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics following a single 400 mg intramuscular injection in healthy adults.</p><h4>References</h4><ol><li><p>Hodge, D, et al., &amp; Marzolini, C (2021). Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. <i>Clinical pharmacokinetics</i> 60(7) 835–853. DOI:<a href=\"https://doi.org/10.1007/s40262-021-01005-1\">10.1007/s40262-021-01005-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33830459/\">https://pubmed.ncbi.nlm.nih.gov/33830459</a></p></li><li><p>Thoueille, P, et al., &amp; Guidi, M (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. <i>Clinical pharmacology and therapeutics</i> 115(6) 1450–1459. DOI:<a href=\"https://doi.org/10.1002/cpt.3240\">10.1002/cpt.3240</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38519844/\">https://pubmed.ncbi.nlm.nih.gov/38519844</a></p></li><li><p>Han, K, et al., &amp; Ford, SL (2024). Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV. <i>Antimicrobial agents and chemotherapy</i> 68(12) e0088024–None. DOI:<a href=\"https://doi.org/10.1128/aac.00880-24\">10.1128/aac.00880-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39440971/\">https://pubmed.ncbi.nlm.nih.gov/39440971</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AJ04_1;
